From vaccines to antiviral sera, drugs against Ebola explore different tracks. However, of the six studies on ways to combat the disease, five are in the stage of animal testing and do not know what reactions can generate in humans.
Several experts debate in WHO headquarters ethical implications of experiencing these substances with those affected by the epidemic in Africa, where until August 8 there were 961 dead and 779 thousand infected.
That official estimate does not include the case in Nigeria confirmed yesterday by the Ministry of Health, or the death of George Combey, fellow Spanish priest Miguel Pajares, who died in the ELWA Hospital in Liberia.
WHO considers accelerate or even "leapfrog" studies, but "maintaining safeguards," said Jean-Marie Okwo-Bele, director of the Department of Vaccines and Immunization of the agency.
Okwo-Bele said he also analyzed using convalescent serum, consisting of antibodies from people who have been cured.
three vaccines
Among the treatments whose studies are more advanced vaccine contained the British firm GlaxoSmithKline (GSK), whose study of -stage safety tests with humans-that will start in September, said Okwo-Bele.
GSK's vaccine is constructed with a viral vector in which two genes of infectious Ebola not inserted. That preparation triggers the production of a protein against which the body will learn to defend themselves.
In addition, the National Institute of Health USA and Thomas Jefferson University developed another inoculation based Ebola vaccine for rabies, which can be used to prevent both diseases in wildlife, although another version is studied to protect veterinarians. This vaccine is still being tested on animals.
Another investigation, said Anthony Fauci, director of the American Institute of Allergy and Infectious Diseases, is the Crucell biopharmaceutical (Johnson & Johnson), which develops a vaccine against Ebola / Marburg virus, according to the lab, and started the first phase safety in humans.
However, this study provides further evidence of phase 1 for late 2015 or early 2016.
three treatments
The ZMapp, a cocktail of three antibodies administered two Americans who were infected in Liberia, is a therapeutic serum "abusively" described as miraculous, according to experts. Although it seems to have "effectively", the administration of two or three patients to draw conclusions, Faucy said.
"Several hundred ZMapp treatments may be available by the end of the year," said Marie-Paule Kieny yesterday, Deputy Director General of the WHO, although "there are other more advanced drugs for other diseases that can be adapted or used against Ebola" he said the expert.
Another drug is the TKM-Ebola, the Tekmira Pharmaceutical, which was slowed by the American drug agency, but that body lifted the suspension in order to make an experimental clinical trial.
The favipiravir (T-705), an antiviral flu that makes Toyama Chemical, a subsidiary of FujiFilm, may emerge as treatment and a spokesman for the company said to be in talks with EU officials to prove it.
keys
Mexico, without risk
- José Antonio Meade, Foreign Secretary, said there are no reports of infected Mexican Ebola in Africa.
- The chancellor explained that working with the Ministry of Health to monitor the situation.
- He said that pending "take care of the flow of international transport seeking to eliminate any risk."
- Meade concluded: "We are calm under these protocols ... no Mexicans there and there is no risk in the country.
The President of Liberia, Ellen Johnson-Sirleaf, announced yesterday that it has asked the United States that makes available an experimental drug against Ebola ZMapp developed there.
Johnson-Sirleaf said Liberia access to this drug may help fight the epidemic and give hope to a population hit by the virus.
"We have known that the drug was administered them to Americans who contracted the disease here, and therefore (the drug) would be welcomed by" he said.
At the same time, the president defended the incineration of the bodies of those killed by the Ebola as the best option to prevent new infections.
Johnson-Sirleaf asked the relatives of the deceased who understand that incineration helps prevent the spread of the virus, which announced that the names of those to be incinerated will be recorded on a memorial.
Meanwhile, the US Congressman Christopher Smith said after meeting with Foreign Minister of Liberia, Augustine Ngafuan that EU will be involved in financing the fight against the virus.
0 comments:
Post a Comment